Unstable angina pectoris and non-Q-wave myocardial infarction
E Cavusoglu1, S K Sharma, W Frishman
1Department of Medicine, Division of Cardiology, Bronx VA Medical Center, New York 10468, USA.
Insights
Unstable angina and non-Q-wave myocardial infarction are serious heart conditions. Risk stratification helps tailor treatments, with medical therapy as the primary approach, while some high-risk patients may benefit from aggressive strategies.
Area of Science:
- Cardiology
- Internal Medicine
Background:
- Unstable angina pectoris and non-Q-wave myocardial infarction represent intermediate syndromes in the coronary artery disease spectrum.
- These conditions share pathophysiologic and clinical features, posing significant morbidity and mortality risks.
Purpose of the Study:
- To discuss risk stratification strategies for patients with unstable angina and non-Q-wave myocardial infarction.
- To outline current and emerging treatment modalities for these acute coronary syndromes.
Main Methods:
- Review of clinical features and biochemical parameters for risk stratification.
- Evaluation of medical therapy, including antiplatelet, anticoagulant, and anti-ischemic agents.
- Assessment of the role of glycoprotein IIb/IIIa antagonists and stress testing.
Main Results:
- Risk stratification allows for tailored treatment and improved resource allocation.
- Medical therapy is the cornerstone of emergent treatment.
- Glycoprotein IIb/IIIa antagonists have demonstrated reductions in morbidity and mortality.
- Stress testing aids in identifying high-risk patients who may benefit from angiography and revascularization.
Conclusions:
- Effective risk stratification is crucial for managing unstable angina and non-Q-wave myocardial infarction.
- While medical management is primary, aggressive strategies may benefit select high-risk individuals.
- Early identification of residual ischemic burden guides decisions regarding coronary angiography and revascularization.
Abstract:
Unstable angina pectoris and non-Q-wave myocardial infarction are clinical syndromes that share many pathophysiologic and clinical features. In the spectrum of coronary artery disease, these syndromes lie between chronic stable angina and Q-wave myocardial infarction. Although both conditions are associated with significant morbidity and mortality, patients presenting with these syndromes can be further risk stratified into higher and lower risk based on a number of readily available clinical features and biochemical parameters. Such risk stratification can allow for more tailored treatment and better resource allocation. Although routine early coronary angiography and revascularization has not been shown to be superior to conservative management, certain high-risk patients may benefit from a more aggressive strategy. Medical therapy with the use of antiplatelet, anticoagulant, and antiischemic agents remains the cornerstone of emergent treatment for patients presenting with these syndromes. The recent demonstration of a reduction in both morbidity and mortality with the glycoprotein IIb/IIIa antagonists has further expanded the armamentarium of available agents. Following initial stabilization, risk stratification with stress testing can help identify patients with a large residual ischemic burden who may benefit from coronary angiography with revascularization if feasible.
Related Concept Videos
01:30Acute Coronary Syndrome I: Introduction
01:19Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations
01:30Angina I: Introduction
01:27Angina II: Classification
01:29Angina III: Clinical Manifestations and Assessment
01:20Angina V: Nursing Management